Background--Recently, we provided evidence that a 1 -adrenergic receptors (ARs) in vascular smooth muscle are regulated by chemokine (C-X-C motif) receptor (CXCR) 4 and atypical chemokine receptor 3 (ACKR3). While we showed that CXCR4 controls a 1 -ARs through formation of heteromeric receptor complexes in human vascular smooth muscle cells (hVSMCs), the molecular basis underlying cross-talk between ACKR3 and a 1 -ARs is unknown.
fundamental signaling unit. 9, 10 In contrast to the traditional view, the concept of GPCR heteromerization assumes that GPCRs function within heteromeric receptor complexes, in which direct physical associations between the receptor partners modulate receptor signaling properties and function. While the existence of numerous GPCR heteromers has been implied based on studies in expression systems, only few of such heteromeric receptor complexes have been validated in native tissues.
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CXCR4 is a typical GPCR that couples to Ga i and recruits barrestin to the receptor. 12 ACKR3 has initially been thought to function as a scavenger receptor, which sequesters chemokine ligands from the cell surface, but does not induce cellular signaling events. 13, 14 Subsequent studies provided evidence that ACKR3 activation does induce b-arrestin-mediated and G protein-independent signaling events. 12, 15, 16 Furthermore, ACKR3 has been described to form heteromeric complexes with CXCR4, leading to preferential activation of b-arrestinmediated signaling pathways over canonical G protein pathways on activation of the receptor complex with C-X-C motif chemokine ligand (CXCL)12. 17, 18 While CXCL12 is the cognate ligand of CXCR4 and ACKR3, 12 macrophage migration inhibitory factor (MIF) and ubiquitin are other endogenous ligands of CXCR4, and MIF and CXCL11 are other endogenous ligands of ACKR3. 12, 19 As recent reports suggest that a-ARs and b-ARs can form heteromeric complexes with other GPCRs, such as other ARs, adenosine A1 receptor, dopamine receptor 4, angiotensin II type I receptor or CXCR4, 11, 20 we studied whether heteromerization of ACKR3 with a 1 -ARs could constitute a molecular mechanism underlying their cross-talk in vascular smooth muscle. Here, we provide evidence that hetero-oligomeric complexes between endogenous ACKR3 and a 1A -AR and between the ACKR3:CXCR4 heteromer and a 1B/D -AR are constitutively expressed in hVSMC, through which ACKR3 regulates a 1 -AR function.
Methods Proteins, Peptides, and Reagents
Phenylephrine (PE), Phentolamine, 5 0 -Methylurapidil, Cyclazosin and BMY 7378 were purchased from Sigma Aldrich, CXCL11 and CXCL12 were from Protein Foundry and TC14012 was from Tocris Biosciences. The peptide analogs of transmembrane (TM) 2 (TM2; YILNLAIADLWVVLTIPVWVVDDD), TM4 (VVCILWLLAFCVSLPDTYYLDD), and TM7 (DDDLHVTQCLSLVH CCVNPVLYSFIN) of ACKR3 were generated using the Fmoc protected amino acids in a solid-phase synthesis on a 433A Applied Biosciences Peptide Synthesizer and Liberty Blue Microwave peptide synthesizer (CEM Corporation) using Fmoc chemistry. The peptides were cleaved from the resin and deprotected with a mixture of 90.0% (v/v) trifluoroacetic acid (TFA) with 2.5% water, 2.5% triisopropyl-silane, 2.5% 2,2 0 -(ethylenedioxy) diethanethiol and 5% thioanisol. Peptides were purified on a preparative (259250 mm) Atlantis C3 reverse phase column (Agilent Technologies) in a 90 minutes gradient of 0.1% (v/v) trifluoroacetic acid in water and 0.1% trifluoroacetic acid in acetonitrile, with a 10 mL/min flow rate. The fractions containing peptides were analyzed on Agilent 6100 LC/MS spectrometer (Agilent Technologies) with the use of a Zorbax 300SB-C3 PoroShell column and a gradient of 5% acetic acid in water and acetonitrile. Fractions that were more than 95% pure were combined and freeze dried.
Cells
hVSMCs, primary aortic smooth muscle cells (ATCC-PCS-100-012), and human embryonic kidney (HEK) 293T cells (ATCC-CRL-11268) were purchased from American Type Culture Collection. hVSMCs were cultured in vascular basal media (ATCC PCS-100-030) supplemented with the vascular smooth muscle growth kit (ATCC PCS-100-042), 100 U/mL penicillin, and 100 lg/mL streptomycin. hVSMCs were used between passages 2 and 5. HEK293T cells were cultured in highglucose Dulbecco's modified Eagle medium containing 10 mg/mL sodium pyruvate, 2 mmol/L L-glutamine, 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 lg/mL streptomycin. The HTLA cell line, a HEK293 cell line stably expressing a tTA-dependent luciferase reporter and a b-arrestin2-TEV
Clinical Perspective
What Is New?
• Heteromeric complexes between atypical chemokine receptor 3 and a 1A/B/D -adrenergic receptors are constitutively expressed in human vascular smooth muscle cells.
• Hetero-oligomerization of a 1B/D -adrenergic receptor with the chemokine (C-X-C motif) receptor 4:atypical chemokine receptor 3 heteromeric complex is required for a 1B/Dadrenergic receptor function.
• Formation of hetero-oligomeric G protein-coupled receptor complexes within the plasma membrane is a dynamic process that depends on the relative abundances of and affinities between available receptor partners.
What Are the Clinical Implications?
• Drugs targeting heteromeric complexes between a1-adrenergic receptors, chemokine (C-X-C motif) receptor 4, and atypical chemokine receptor 3 could provide new pharmacological approaches to regulate vascular function in disease conditions. • Dynamic alterations in the formation of hetero-oligomeric receptor complexes could explain biological variability of G protein-coupled receptor-mediated functions.
fusion gene, 21 was generously provided by the laboratory of Dr Bryan Roth and maintained in high glucose Dulbecco's modified Eagle medium supplemented with 10% (vol/vol) heat-inactivated FBS, 19 nonessential amino acids, 100 U/ mL penicillin, 100 lg/mL streptomycin, 50 lg/mL hygromycin B, and 2 lg/mL puromycin. All cells were cultured in a humidified environment at 37°C, 5% CO 2 .
Proximity Ligation Assays
Proximity ligation assays (PLAs) were performed as previously described in detail. 4, 8, 22 In brief, cells were grown and fixed on 8-well chamber slides (Nunc). Cells were fixed with 4% (wt/vol) paraformaldehyde for 15 minutes at room temperature and then blocked overnight at 4°C with 3% (wt/vol) BSA in PBS. To visualize individual receptors, slides were incubated with rabbit anti-HA (Abcam 9110), mouse anti-FLAG (Sigma F1804), mouse anti-ACKR3 (R&D MAB42273), rabbit anti-a 1A -AR (Abcam Ab137123), rabbit anti-a 1B -AR (Abcam Ab169523), goat anti-a 1D -AR (Santa Cruz SC27099), or goat anti-CXCR4 (Abcam Ab1670) at 37°C for 105 minutes in a humidifying chamber. To visualize receptor-receptor interactions, slides were incubated with a combination of rabbit anti-HA (Abcam 9110) and mouse anti-FLAG (Sigma F1804), mouse anti-ACKR3 (R&D MAB42273), and goat anti-CXCR4 (Abcam 1670) or rabbit anti-a 1A -AR (Abcam Ab137123) or rabbit anti-a 1B -AR (Abcam Ab169523) or goat anti-a 1D -AR (Santa Cruz SC27099) or with a combination of goat anti-CXCR4 (Abcam 1670) and rabbit anti-a 1A -AR (Abcam Ab137123) or rabbit anti-a 1B -AR (Abcam Ab169523) or rabbit anti-CXCR4 (Alomone Labs ACR-014) and goat anti-a 1D -AR (Santa Cruz SC27099) at 37°C for 105 minutes in a humidifying chamber. All antibodies were used in dilutions of 1:500. Slides were then washed with PBS and incubated (60 minutes at 37°C in a humidifying chamber) with secondary species-specific antibodies conjugated with plus and minus Duolink II PLA probes (1:5), as appropriate. Negative control slides were incubated with omission of one primary antibody. Slides were washed again with PLA wash buffer A (Duolink II) and then incubated with ligation-ligase solution (30 minutes at 37°C in a humidifying chamber), washed with PLA wash buffer A and then incubated with amplification-polymerase solution (100 minutes at 37°C in a humidifying chamber). Slides were then washed twice with PLA wash buffer B (Duolink II), once with 0.019 PLA wash buffer B and allowed to dry. Slides were then mounted with a minimal volume of Duolink II mounting medium with 4 0 ,6-diamidino-2-phenylin- 
Co-Immunoprecipitation Analyses of Receptor Interactions
Co-immunoprecipitation experiments with hVSMCs were performed using the Thermo Scientific Pierce Co-immunoprecipitation Kit (catalog No. 26149), as previously described. 
Western Blotting
Western blotting with rabbit anti-ACKR3 (Abcam Ab38089), rabbit anti-a 1A -AR (Abcam Ab137123), rabbit anti-a 1B -AR (Abcam Ab169523), goat anti-a 1D -AR (Santa Cruz SC27099), and mouse anti-a 2C -AR (Abcam Ab167433) in combination with anti-rabbit, goat, or mouse IgG horseradish peroxidaselinked whole antibody (GE Healthcare and Sigma Aldrich) was performed as previously described.
Gene Silencing via RNA Interference ACKR3 and CXCR4 siRNA gene silencing was performed as previously described. 25 In brief, hVSMCs were grown in 2 mL of Accell siRNA delivery media per well (Dharmacon) in 6-well plates (Nunc). Commercially available Accell ACKR3 and CXCR4 siRNA were reconstituted with 19 siRNA buffer to a stock concentration of 100 lmol/L. Cells were then transfected with 1 lmol/L of ACKR3/CXCR4 siRNA and incubated for 72 hours at 37°C, 5% CO 2 . Accell NT siRNA pool was used as negative control. After 72 hours, cells were assayed for receptor cell-surface expression and used for signaling experiments.
GPCR Gene Transfections
HEK293T cells were transiently transfected with 1.5 lg of DNA encoding either human influenza hemagglutinin (HA)-tagged ACKR3 (HA-ACKR3), FLAG-ACKR3, HA-CXCR4, FLAG-a 1a -AR, FLAG-a 1b -AR, or FLAG-a 1d -AR with a combination of 2 GPCR encoding DNAs, as indicated (all plasmids from Addgene), using Lipofectamine 3000 as per manufacturer's protocol. Empty vector, pcDNA3, was used as a control. Twenty-four hours later, cells were fixed on chamber slides for PLA.
IP 3 ELISA
Inositol trisphosphate (IP 3 ) ELISAs were purchased from LS Bio and performed according to the manufacturer's protocol (LS BIO F10644). In brief, hVSMCs were grown to confluency in 6-well dishes (Nunc) and then treated as described in the Results section. Cells were then washed once with cold PBS, 225 lL of cold PBS was added to each well, and cells were lysed by ultrasonication. The cell lysate was centrifuged for 10 minutes at 4°C at 1500g to remove cellular debris. The total protein concentration in the supernatant was determined with the Bio-Rad DC Protein Assay according to the manufacturer's protocol (Bio-Rad 500-0116). Equivalent amounts of total protein were added to the ELISA strips diluted in the provided sample diluent (1:5 and 1:10). The assay was then completed as per the manufacturer's protocol. Optical densities were read on a Biotek Synergy II microplate reader (absorbance at 450 nm) and IP 3 concentrations were extrapolated from the standard curve.
PRESTO-Tango b-Arrestin Recruitment Assay
The PRESTO-Tango (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation) assay was performed as recently described. 21 The ACKR3 and a 1B -AR-Tango plasmids were a gift from Dr Bryan Roth (Addgene plasmids #66265 and #66214). HTLA cells (2.5910 5 /well) were seeded in a 6-well plate and transfected with 1.5 lg of the Tango plasmids using Lipofectamine 3000. The following day, transfected HTLA cells (1910 5 cells/well) were plated onto
Poly-L-Lysine precoated 96-well microplates and allowed to attach to the plate surface for at least 4 hours before treatment. Proteins used for treatment were prepared in twice the final concentration in culture media, added at a 1:1 (vol/ vol) ratio and incubated overnight at 37°C, 5% CO 2 in a humidified environment. The following morning, media were removed from cell culture plates and replaced with a 100-lL 1:5 mixture of Bright-Glo (Promega) and 19 Hanks' balanced salt solution, 20 mmol/L HEPES solution. Plates were then incubated at room temperature before measuring luminescence on a Biotek Synergy II plate reader.
Pressure Myography
All procedures involving animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, 8th Edition, and were approved by the Institutional Animal Care and Use Committee of Loyola University Chicago. Pressure myography was performed as previously described in detail with slight modifications. 
Data Analyses
Data are expressed as meanAESEM from independent experiments that were performed on different days. Data were analyzed using GraphPad Prism 7 software. 
Results

ACKR3 Agonists Inhibit G q -Mediated Signaling on a 1 -AR Activation
We have previously shown that ACKR3 activation antagonizes vasoconstriction of isolated mesenteric resistance arteries upon stimulation with the selective a 1 -AR agonist PE. 3 Because the effects of ACKR3 activation on PE-induced intracellular signaling events in hVSMCs are unknown, we evaluated the effects of the natural ACKR3 agonists CXCL11 and CXCL12 and of the synthetic peptide agonist TC14012, which is also a CXCR4 antagonist, using IP 3 production in hVSMCs upon stimulation with PE as a read-out for G q -mediated signaling on a 1 -AR activation. We first confirmed ACKR3 agonist activity of the ligands in a b-arrestin 2 recruitment assay (PRESTOTango 21 ). As shown in Figure 2A , the EC 50 for b-arrestin 2 recruitment to ACKR3 was 16.5AE4.9 nmol/L for CXCL11, 2.4AE0.3 nmol/L for CXCL12, and 87.5AE19.0 nmol/L for TC14012. The efficacy of TC14012 to recruit b-arrestin 2 to ACKR3 was lower than the efficacy of the natural chemokine agonists. PE stimulation of hVSMCs increased cellular IP 3 concentrations 5.3-fold. Pretreatment of cells with all ACKR3 agonists abolished this response, indicating that ACKR3 activation inhibits a 1 -AR-mediated signaling ( Figure 2B ).
ACKR3 Forms Heteromeric Complexes With a 1A/ B/D -AR
Next, we studied whether recombinant ACKR3 would be able to form heteromeric complexes with recombinant a 1 -AR subtypes in HEK293T cells. We used proximity ligation assays (PLAs) to visualize and quantify individual receptors and receptor-receptor interactions at single molecule resolution. 26 Heteromerization between ACKR3 and CXCR4 and between CXCR4 and a 1a -AR was used as a positive control in PLA experiments because both receptor pairs have previously been shown to interact in expression systems. 8, 17 When N- (Figure 4C) . a 1A/B/D -AR and a 2B -AR were detectable in ACKR3 immunoprecipitates ( Figure 4D through 4G) , whereas a 2C -AR could not be detected ( Figure 4H ). It should be noted that we observed a band of 50 kDa in the ACKR3 immunoprecipitate in Western blot experiments with anti-a 1D -AR, but we were unable to detect a 1D -AR in the hVSMC lysate (input). We interpret this observation to reflect low abundance of a 1D -AR on hVSMC and high enrichment of a 1D -AR in the ACKR3 immunoprecipitate. Furthermore, the band corresponding to a 1A -AR in the ACKR3 immunoprecipitate migrated with a slightly lower molecular mass (46.1 kDa; 95% confidence interval, 42.2-50.5) than in the hVSMC lysate (49 kDa; 95% confidence interval, 44.8-53.8), which could be explained by differences in posttranslational receptor modifications or partial proteolytic processing, which may have occurred during the experimental procedure. While we observed 3 bands for a 2B -AR in the cell lysate, only the band migrating slightly below 50 kDa was detectable in the ACKR3 immunoprecipitate. This band matches well with the predicted molecular mass of 49.9 kDa for human a 2B -AR (UniProtKB-P18089). Collectively, our observations suggest that heteromeric complexes between ACKR3 and a 1A/B/D -AR are constitutively expressed in hVSMCs.
ACKR3 Silencing Inhibits a 1 -AR
To assess the functional role of heteromeric complexes between ACKR3 and a 1A/B/D -AR on a 1 -AR function, we then aimed to reduce heteromeric complexes in hVSMCs by ACKR3 knockdown with siRNA. Typical PLA images for the detection of individual receptors and receptor-receptor interactions in hVSMCs after incubation with NT siRNA and ACKR3 siRNA are shown in Figure 5A and the quantifications of the PLA signals from 4 independent experiments are shown in Figure 5B and 5C. Incubation of hVSMCs with siRNA for ACKR3 reduced PLA signals for ACKR3 by more than 70%, as compared with cells incubated with NT siRNA. PLA signals for a 1A/B/D -AR or CXCR4 were indistinguishable between hVSMCs incubated with NT or ACKR3 siRNA ( Figure 5B ).
Quantification of the PLA signals for receptor-receptor interactions showed that siRNA knockdown of ACKR3 significantly reduced ACKR3:a 1B/D -AR and ACKR3:CXCR4 interactions but did not affect ACKR3:a 1A -AR or CXCR4:a 1A -AR interactions ( Figure 5C ). When hVSMCs were tested for PEinduced IP 3 production after incubation with NT siRNA or ACKR3 siRNA, we observed that PE increased cellular IP 3 concentrations 4.8-fold after incubation with NT siRNA but failed to increase IP 3 concentrations in cells after incubation with ACKR3 siRNA ( Figure 5D ). Because ACKR3 siRNA knockdown did not significantly reduce ACKR3:a 1A -AR but abolished PE-induced IP 3 production in hVSMCs, we then evaluated the relative contribution of the a 1 -AR subtypes to this signaling response. As shown in Figure 5E , PE-induced IP 3 production could be inhibited with the nonselective a 1 -AR antagonist phentolamine and with the selective a 1B/D -AR antagonists cyclazosin and BMY 7378, respectively. In contrast, the selective a 1A -AR antagonist 5 0 -methylurapidil did not inhibit PE-induced IP 3 production in hVSMCs. We previously showed that CXCR4 knockdown reduces heteromeric complexes between CXCR4 and a 1A/B -AR and between CXCR4 and ACKR3, leading to loss of a 1 -AR signaling. 8 Because CXCR4 likely exists as a homodimer and also within CXCR4:ACKR3 heteromeric were reduced to 30AE3% and 36AE5% of the signals for cells incubated with NT siRNA, respectively. Consistent with our previous findings, 8 we observed that PE-induced IP 3 production was abolished after incubation of hVSMCs with CXCR4 siRNA or ACKR3 siRNA, as compared with hVSMCs incubated with NT siRNA ( Figure 6E ).
TM Domain-Derived Peptide Analogs of ACKR3
Interfere With Receptor Heteromerization TM-derived peptide analogs of GPCRs, including TM peptide analogs of CXCR4 and b 2 -AR, have previously been shown to interfere with receptor heteromerization and function. 4, 27, 28 Thus, we tested whether peptide analogs of TM2, TM4, and TM7 of ACKR3 would also be able to affect formation of heteromeric ACKR3 complexes in PLA experiments. Representative PLA images for the visualization of individual receptors and receptor-receptor interactions after incubation of hVSMCs with vehicle or ACKR3 TM peptide analogs are shown in Figure 7A and 7B. The quantifications of the corresponding PLA signals for individual receptors and receptor-receptor interactions from 3 independent experiments are shown in Figure 8A and 8B. The TM peptide analogs did not significantly affect the number of PLA signals for ACKR3, a 1A/B/D -AR, or CXCR4 ( Figure 8A ). When PLA was performed to detect receptor-receptor interactions, however, we observed differential effects of the TM peptide analogs on the number of PLA signals in hVSMCs ( Figure 8B) signals for ACKR3:CXCR4 heteromeric complexes were reduced after incubation with all TM peptide analogs (TM2>TM4>TM7), all peptide analogs significantly increased signals for CXCR4:a 1A -AR. Furthermore, the TM2 and TM4 peptides also increased signals for CXCR4:a 1B -AR complexes but did not affect signals for CXCR4:a 1D -AR complexes. The TM7 peptide did not significantly affect signals for CXCR4:a 1B -AR or CXCR4:a 1D -AR complexes.
TM Domain-Derived Peptide Analogs of ACKR3 Interfere With Receptor Function
We then studied whether the TM peptide analogs of ACKR3 modulate signaling of recombinant ACKR3 and a 1b -AR. None of the TM peptide analogs activated ACKR3 in b-arrestin recruitment assays ( Figure 9A ). The TM2 peptide analog, however, significantly inhibited CXCL12-induced b-arrestin 2 recruitment Figure 9B) . None of the TM peptide analogs affected PEinduced b-arrestin 2 recruitment to a 1b -AR ( Figure 9C ).
Next, we tested whether the TM peptide analogs interfere with signaling of endogenous a 1 -AR in hVSMCs. While the TM7 peptide analog did not influence PE-induced IP 3 production in hVSMCs, the TM2 and TM4 peptide analogs inhibited this response ( Figure 9D ). Next, we reevaluated the effects of CXCL12 on PE-induced IP 3 Figure 9 . Peptides derived from transmembrane domains of atypical chemokine receptor 3 (ACKR3) modulate receptor function. A, b-arrestin 2 recruitment assay (PRESTO-Tango) for ACKR3. Cells were treated with chemokine (C-X-C motif) ligand 12 (CXCL12) or transmembrane (TM) 2/4/ 7 peptide analogs. RLU (%): relative luminescence units in percentage of the RLU after treatment with 1 lmol/L CXCL12 (=100%). n=3 independent experiments. B, b-arrestin 2 recruitment assay (PRESTO-Tango) for ACKR3. Cells were treated with CXCL12 or CXCL12 plus 10 lmol/L of the TM2/4/7 peptide analogs. RLU (%): relative luminescence units in % of the RLU after treatment with 1 lmol/L CXCL12 (=100%). n=4 independent experiments. C, b-arrestin 2 recruitment assay (PRESTO-Tango) for a 1b -adrenergic receptor (AR). Cells were treated with phenylephrine (PE) or PE plus 10 lmol/L of the TM2/4/7 peptide analogs. RLU (%): relative luminescence units in percentage of the RLU after treatment with 10 mmol/L PE (=100%). n=3 independent experiments. D, Inositol trisphosphate (IP 3 ) production was measured in human vascular smooth muscle cells (hVSMCs) pretreated with vehicle or the TM2/4/7 peptide analogs (10 lmol/L, 30 minutes at 37°C) and then stimulated with vehicle or 1 lmol/L PE for 5 minutes. *P<0.05 vs vehicle/no PE; # P<0.05 vs vehicle plus PE, n=4 independent experiments. E, IP 3 production was measured in hVSMCs pretreated with vehicle or the TM2/4/7 peptide analogs (10 lmol/L, 30 minutes at 37°C) plus vehicle or CXCL12 (1 lmol/L, 15 minutes at 37°C) and then stimulated with vehicle or 1 lmol/L PE for 5 minutes. *P<0.05 vs vehicle only, n=3 independent experiments. F and G, Pressure myography with rat mesenteric arteries. Arteries were pressurized to 80 mm Hg and pretreated with vehicle, 10 lmol/L (F) or 100 lmol/L (G) of the TM2/4/7 peptide analogs. Increasing concentrations of PE were then added to the vessel bath and doseresponse curves generated. % o.d. indicates outer artery diameter in percentage of the outer diameter in the absence of PE. n=3 independent experiments. production after incubation of hVSMCs with the TM peptides ( Figure 9E ). As observed in Figure 2B , PE-induced IP 3 production was abolished after pretreatment with CXCL12 alone and after pretreatment with a combination of CXCL12 and the individual TM peptides.
To assess whether the effects of the TM peptide analogs on PE-mediated signaling events in cells correspond to their effects on vascular smooth muscle function, we then performed pressure myography experiments with isolated rat mesenteric arteries ( Figure 9F and 9G) . The TM peptide analogs did not affect PE-induced vasoconstriction when tested at a concentration of 10 lmol/L ( Figure 9F) . When tested at a 10-fold higher concentration (Figure 9G 
Discussion
In the present study, we provide evidence that heteromeric complexes between ACKR3 and a 1A/B/D -AR are constitutively expressed in hVSMCs. Our findings suggest that heterooligomerization of a 1B/D -AR with the CXCR4:ACKR3 heteromeric complex is required for a 1B/D -AR function ( Figure 10A ). Furthermore, our observations indicate that the formation of hetero-oligomeric GPCR complexes within the plasma membrane is a dynamic process that depends on the relative abundances of and affinities between available receptor partners ( Figure 10B ).
The finding that ACKR3 agonists inhibited a 1 -AR-mediated IP 3 production is consistent with the effects of the ACKR3 agonists on a 1 -AR-mediated constriction of isolated resistance arteries that we previously described and confirms functional cross-talk between ACKR3 and a 1 -ARs in hVSMCs. 3 Furthermore, the observed effects of CXCL12 in the present study are consistent with our previous findings that CXCL12 functions predominantly as an ACKR3 agonist in isolated mesenteric rat arteries, which attenuates PE-induced vasoconstriction, and during the cardiovascular stress response to hemorrhagic shock in rats, where CXCL12 impairs hemodynamic stability and blood pressure. 3 This behavior could be explained by the higher affinity of CXCL12 for ACKR3 than for CXCR4. 16 CXCL12, however, also enhanced the potency of PE to increase blood pressure in normal animals via CXCR4, which indicates that its functions depend on the relative contribution of CXCR4 and ACKR3 to the specific experimental or pathophysiological environment. 8 We detected that recombinant and endogenous ACKR3 and a 1A/B/D -AR are in close proximity in cells. Because endogenous a 1A/B/D -AR could also be co-immunoprecipitated with ACKR3 in hVSMCs, these data suggest that ACKR3 physically interacts with a 1A/B/D -AR and that the close proximity between the receptor partners that we detected by PLA corresponds to direct receptor-receptor interactions. In contrast to interaction patterns between CXCR4 and a 1/2 -AR that we previously observed, our current findings indicate that ACKR3 also heteromerizes with a 2B -AR in hVSMCs, suggesting selectivity of the observed receptor-receptor interactions. 8 We have previously shown that siRNA knockdown of CXCR4 in hVSMCs reduces heteromeric CXCR4:ACKR3 and CXCR4:a 1A/B -AR complexes and inhibits a 1 -AR function upon PE stimulation. 8 The findings of the present study that siRNA knockdown of either ACKR3 or CXCR4 reduces heteromeric complexes between ACKR3:a 1B/D -AR and between CXCR4: a 1B/D -AR suggest that a 1B/D -AR form hetero-oligomeric complexes with the CXCR4:ACKR3 heteromer and that such hetero-oligomerization is required for a 1B/D -AR function. This assumption is supported by our observations on the effects of the TM2 peptide analog of ACKR3. While this peptide reduced a 1B/D -AR:ACKR3 and ACKR3:CXCR4 heteromerization, abolished PE-induced IP 3 production in hVSMCs, and inhibited PEinduced constriction of isolated mesenteric arteries, it also increased the number of CXCR4:a 1A/B -AR complexes (Figure 10B ). As the TM2 peptide analog did not inhibit b-arrestin 2 recruitment to recombinant a 1b -AR on PE stimulation, these findings further indicate that it inhibits a 1B/D -AR function through interference with receptor hetero-oligomerization. In combination with the observation that CXCL12 did not enhance PE-induced signaling in hVSMCs in the presence of the TM2 peptide, these data support the notion that the hetero-oligomeric complex between the CXCR4:ACKR3 heteromer and a 1B/D -AR, but not the heteromer between a 1B/D -AR and the CXCR4 protomer or homodimer, regulates a 1B/D -AR function in hVSMCs. The observation that the TM7 peptide did not affect PE-induced signaling is consistent with this concept as it did not reduce ACKR3:a 1B/D -AR and CXCR4: a 1B/D -AR, despite partial interference with ACKR3:CXCR4 heteromerization ( Figure 10B ). Research on the biological roles of ACKR3 has been hampered by the lack of pharmacological ACKR3 inhibitors. The findings of the present study identify the TM2 peptide analog as an ACKR3 inhibitor without intrinsic agonist activity within the tested range of concentrations. Thus, we cannot exclude that inhibition of ACKR3 also contributes to the inhibitory effects of the TM2 peptide analog on a 1 -AR signaling in hVSMCs. Nevertheless, such a mechanism would be consistent with the assumption that conformational changes of ACKR3 on agonist or antagonist binding inhibit a 1B/D -AR via allosteric interactions within the hetero-oligomeric receptor complex.
Inositol Trisphosphate Vasoconstriction
We observed that ACKR3 knockdown did not affect CXCR4:a 1A -AR heteromerization and that CXCR4 knockdown did not affect ACKR3:a 1A -AR heteromerization. Furthermore, all TM peptide analogs interfered with ACKR3:CXCR4 heteromerization but increased CXCR4:a 1A -AR heteromers. As we have previously shown that CXCR4 knockdown in hVSMCs reduces CXCR4:a 1A -AR heteromers, 8 these observations suggest that a 1A -AR predominantly forms heteromeric complexes with CXCR4 and ACKR3 protomers or homodimers, whereas a 1B/D -AR preferentially form hetero-oligomeric complexes with the CXCR4:ACKR3 heteromer. We have previously shown that partial depletion of vascular smooth muscle CXCR4 in a Cre-lox mouse model did not reduce CXCR4:a 1A/B -AR heteromerization. 4 Similarly, partial depletion of ACKR3 in hVSMCs did not reduce ACKR3:a 1A -AR heteromerization in the present study. These observations imply that the formation of heteromeric receptor complexes is not a direct function of total expression levels of a single receptor and depends on relative affinities between interacting receptor partners and their relative abundances on the cell surface. In such a system, ACKR3:a 1A -AR heteromerization may be favored over the formation of other ACKR3 heteromers and ACKR3 protomers or homodimers. Reduction of ACKR3:a 1A -AR heteromerization would then only occur when the relative abundance of ACKR3 falls below the number of a 1A -ARs that are available for heteromerization. We observed that the ACKR3 TM peptide analogs selectively interfered with ACKR3 heteromerization but also increased the number of other ACKR3 and CXCR4 heteromeric complexes. These findings suggest that binding of the peptides to their corresponding TM receptor domains interferes with distinct receptor heteromerization interfaces, either by direct blockade of interactions sites or via allosteric effects on the target receptor conformation. Disruption of heterooligomeric receptor complexes by the TM peptides then leads to the assembly of newly formed hetero-oligomeric receptor complexes, depending on the relative affinities for and abundances of available receptor partners and receptor interaction sites (Figure 10 ). Thus, these observations suggest that the formation of hetero-oligomeric receptor complexes within the plasma membrane is a dynamic process, in which interference with heteromerization between receptor partners shifts the patterns of receptor heteromerization within the entire receptor network towards a new equilibrium. This assumption would be consistent with previous observations that recombinant GPCRs exist on the cell surface in a dynamic equilibrium between monomeric receptors and dimeric/oligomeric receptor complexes. [29] [30] [31] Provided that receptor heteromerization modulates the pharmacological properties of each receptor partner, such regulation of heteromeric receptor complex formation implies that receptor function is rapidly adapted to the specific environment and explains biological variability of GPCR-mediated functions. We did not employ an unrelated control peptide, eg a scrambled peptide of similar amino acid composition, in our experiments. Nevertheless, the differential effects of the TM peptide analogs on receptor heteromerization and function serve as rigorous controls for each other.
Although depletion of ACKR3 in hVSMCs and incubation of hVSMCs with the TM2 and TM4 peptide analogs did not affect expression levels of ACKR3:a 1A -AR complexes, a 1 -ARmediated signaling on PE stimulation was abolished under both conditions. Furthermore, the TM7 peptide increased the number of ACKR3:a 1A -AR heteromers on hVSMCs but did not affect PE-induced a 1 -AR function. PE-induced IP 3 production, however, was not sensitive to the selective a 1A -AR antagonist 5 0 -methylurapidil but could be inhibited with a pan a 1 -AR antagonist and with selective a 1B/D -AR antagonists. This suggests that the relative contribution of a 1A -AR to the combined a 1 -AR response is limited under our experimental conditions, which is consistent with the relative functional relevance of a 1 -AR subtypes previously reported. [32] [33] [34] Thus, we cannot currently comment on the functional role of a 1A -AR:ACKR3 heteromers. Similarly, possible functions of ACKR3:a 2B -AR heteromeric complexes remain to be determined in future studies.
Conclusions
We show that recombinant and endogenous ACKR3 form heteromeric complexes with a 1 -AR, that endogenous heteromeric ACKR3:a 1B/D -AR complexes can be disrupted with TMderived peptide analogs of ACKR3 without altering expression levels of individual receptors, and that disruption of heteromeric ACKR3:a 1B/D -AR complexes results in the loss of a 1B/D -AR function. Thus, our findings fulfill recently proposed criteria for GPCR heteromers in native tissues. 11 Our observations suggest that a 1B/D -AR function depends on direct physical interactions with the ACKR3:CXCR4 heteromer, which may serve as a molecular scaffold to maintain a 1B/D -AR in a functional configuration within the plasma membrane. In combination with our previous findings, 3, 4, 8 these data further suggest that ACKR3 on agonist binding negatively regulates the activity of a 1B/D -AR, whereas CXCR4 on agonist binding sensitizes a 1B/D -AR function via allosteric interactions within the hetero-oligomeric receptor complex ( Figure 10A ). Our findings provide new insights into the regulation of a 1 -AR in hVSMCs and highlight the functional relevance of GPCR hetero-oligomerization for GPCR function. Furthermore, we provide initial evidence that hetero-oligomerization of endogenous GPCRs is a dynamic process, which could explain biological variability of GPCR-mediated signaling events and functions. We believe that drugs targeting heteromeric complexes between a 1 -AR, CXCR4, and ACKR3 could provide new pharmacological approaches to regulate vascular function in disease conditions.
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